Embase
Embase is a biomedical and pharmacological database published by Elsevier. It contains indexed literature that is not readily available in other databases. Embase includes articles from journals that are not indexed by other biomedical sources, particularly those from Europe.
Overview[edit]
Embase was launched in 1974 by Excerpta Medica, a Dutch publishing company that was later acquired by Elsevier. The database contains over 32 million records from over 8,500 currently indexed journals. Embase's literature is primarily from 1947 to the present, with selected coverage from 1902.
Content[edit]
Embase covers the fields of drug development, clinical guidelines, treatment evaluation, drug safety, pharmacoeconomics, and pharmacoepidemiology. It also includes the fields of molecular biology, biotechnology, health policy management, public health, occupational health, environmental health, drug dependence and abuse, psychiatry, forensic science, and biomedical engineering.
Features[edit]
Embase provides access to the most recent and relevant medical literature with a strong focus on evidence-based medicine. It includes unique non-English content and literature from the most important types of evidence, such as systematic reviews, health technology assessments and controlled trials. Embase's comprehensive indexing process uses the Emtree controlled vocabulary, which is updated annually to ensure all records are indexed accurately.
Access[edit]
Access to Embase is generally provided through institutional subscriptions, such as those held by universities and medical schools. Some public libraries and other non-profit institutions also provide access. Individuals can purchase short-term access to Embase.
See also[edit]
References[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian